套细胞淋巴瘤中的细胞周期调控：基因组学与治疗。
Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy.
机构信息
Department of Pathology and Laboratory Medicine, 1300 York Avenue, C316, New York, NY 10065, USA.
Department of Pathology and Laboratory Medicine, Program in Immunology and Microbial Pathogenesis, Weill Cornell Medical College, 1300 York Avenue, Room C316, New York, NY 10065, USA.
出版信息
Hematol Oncol Clin North Am. 2020 Oct;34(5):809-823. doi: 10.1016/j.hoc.2020.05.003. Epub 2020 Aug 1.
Abstract
Cell cycle dysregulation caused by aberrant cyclin D1 and CDK4 expression is a major determinant for proliferation of cancer cells in mantle cell lymphoma (MCL). Inhibition of CDK4/6 induces G1 arrest of MCL cells in patients, appearing to deepen and prolong the clinical response to partner agents. This article reviews aberrations of cell cycle genes in MCL cells and clinical trials of CDK4/6 inhibitors for MCL. Integrative longitudinal functional genomics is discussed as a strategy to discover genomic drivers for resistance in cancer cells and cancer-immune interactions that potentially contribute to the clinical response to palbociclib combination therapy in MCL.
摘要
细胞周期失调是套细胞淋巴瘤（MCL）中癌细胞增殖的主要决定因素，其由异常 cyclin D1 和 CDK4 表达引起。CDK4/6 抑制剂可诱导 MCL 患者细胞 G1 期阻滞，似乎加深和延长了对联合用药的临床反应。本文综述了 MCL 细胞中细胞周期基因的异常以及 CDK4/6 抑制剂治疗 MCL 的临床试验。还讨论了整合的纵向功能基因组学策略，以发现癌细胞耐药的基因组驱动因素以及可能有助于 MCL 患者对帕博西利联合治疗产生临床反应的癌-免疫相互作用。
相似文献
1
Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy.套细胞淋巴瘤中的细胞周期调控：基因组学与治疗。
Hematol Oncol Clin North Am. 2020 Oct;34(5):809-823. doi: 10.1016/j.hoc.2020.05.003. Epub 2020 Aug 1.
2
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1.CDK4/CDK6 抑制诱导持久的早期 G1 期阻滞，通过 PIK3IP1 重编程淋巴瘤细胞对 PI3Kδ 抑制的持久反应。
Cell Cycle. 2013 Jun 15;12(12):1892-900. doi: 10.4161/cc.24928. Epub 2013 May 15.
3
A defect of the INK4-Cdk4 checkpoint and Myc collaborate in blastoid mantle cell lymphoma-like lymphoma formation in mice.INK4-Cdk4 检查点缺陷和 Myc 在小鼠类原始神经外胚层肿瘤样套细胞淋巴瘤的形成中协同作用。
Am J Pathol. 2012 Apr;180(4):1688-701. doi: 10.1016/j.ajpath.2012.01.004. Epub 2012 Feb 9.
4
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.针对PI3K抑制的细胞周期重编程克服了套细胞淋巴瘤纵向功能基因组学揭示的复发特异性C481S BTK突变。
Cancer Discov. 2014 Sep;4(9):1022-35. doi: 10.1158/2159-8290.CD-14-0098. Epub 2014 Jul 31.
5
Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA.周期蛋白 D1-CDK4 活性通过阻断自噬介导的 NOXA 蛋白水解来驱动套细胞淋巴瘤对硼替佐米的敏感性。
J Hematol Oncol. 2018 Sep 4;11(1):112. doi: 10.1186/s13045-018-0657-6.
6
Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.套细胞淋巴瘤细胞主要表达细胞周期蛋白D1a亚型，并且对CDK4激酶活性的选择性抑制高度敏感。
Blood. 2006 Sep 1;108(5):1744-50. doi: 10.1182/blood-2006-04-016634. Epub 2006 May 11.
7
Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.靶向滑膜肉瘤中的细胞周期蛋白依赖性激酶：帕博西尼作为滑膜肉瘤患者的一种潜在治疗方法。
Ann Surg Oncol. 2016 Sep;23(9):2745-52. doi: 10.1245/s10434-016-5341-x. Epub 2016 Jun 22.
8
Targeting CDK4/6 in mantle cell lymphoma.靶向套细胞淋巴瘤中的细胞周期蛋白依赖性激酶4/6
Ann Lymphoma. 2020 Mar;4. doi: 10.21037/aol.2019.12.01.
9
Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.基于BET蛋白拮抗剂的联合用药在对依鲁替尼敏感或耐药的套细胞淋巴瘤细胞中的协同活性。
Blood. 2015 Sep 24;126(13):1565-74. doi: 10.1182/blood-2015-04-639542. Epub 2015 Aug 7.
10
Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV.通过套细胞淋巴瘤（MCL）和套细胞淋巴瘤胚样变异型（MCL - BV）的基因表达谱检测到的套细胞淋巴瘤胚样变异型（MCL - BV）中的细胞周期改变
Diagn Mol Pathol. 2003 Mar;12(1):35-43. doi: 10.1097/00019606-200303000-00005.
引用本文的文献
1
Ironomycin induces mantle cell lymphoma cell death by targeting iron metabolism addiction.铁霉素通过靶向铁代谢成瘾诱导套细胞淋巴瘤细胞死亡。
Theranostics. 2025 Feb 3;15(7):2834-2851. doi: 10.7150/thno.101821. eCollection 2025.
2
Exploring the anti-atherosclerosis mechanism of ginsenoside Rb1 by integrating network pharmacology and experimental verification.通过整合网络药理学和实验验证来探究人参皂苷 Rb1 的抗动脉粥样硬化机制。
Aging (Albany NY). 2024 Mar 27;16(8):6745-6756. doi: 10.18632/aging.205680.
3
Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion.细胞周期蛋白依赖性激酶4/6抑制剂帕博西尼与BCL2抑制剂维奈托克在无RB1缺失的套细胞淋巴瘤实验模型中具有协同作用。
Exp Hematol Oncol. 2024 Mar 25;13(1):34. doi: 10.1186/s40164-024-00499-2.
4
Resistance to PRMT5-targeted therapy in mantle cell lymphoma.套细胞淋巴瘤中对 PRMT5 靶向治疗的耐药性。
Blood Adv. 2024 Jan 9;8(1):150-163. doi: 10.1182/bloodadvances.2023010554.
5
Ambra1 modulates the sensitivity of mantle cell lymphoma to palbociclib by regulating cyclin D1.安布瑞通过调节细胞周期蛋白 D1 来调节套细胞淋巴瘤对帕博西利的敏感性。
Sci Rep. 2023 May 24;13(1):8389. doi: 10.1038/s41598-023-35096-6.
6
p53 directly downregulates the expression of CDC20 to exert anti-tumor activity in mantle cell lymphoma.p53直接下调CDC20的表达，从而在套细胞淋巴瘤中发挥抗肿瘤活性。
Exp Hematol Oncol. 2023 Mar 7;12(1):28. doi: 10.1186/s40164-023-00381-7.
本文引用的文献
1
A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma.帕博西尼联合硼替佐米治疗既往治疗的套细胞淋巴瘤的 I 期临床试验。
Leuk Lymphoma. 2019 Dec;60(12):2917-2921. doi: 10.1080/10428194.2019.1612062. Epub 2019 May 23.
2
The broken cycle: E2F dysfunction in cancer.断裂的循环：E2F 功能障碍与癌症。
Nat Rev Cancer. 2019 Jun;19(6):326-338. doi: 10.1038/s41568-019-0143-7.
3
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.一项在既往治疗的套细胞淋巴瘤中应用伊布替尼联合哌柏西利的 1 期临床试验。
Blood. 2019 Mar 14;133(11):1201-1204. doi: 10.1182/blood-2018-11-886457. Epub 2019 Jan 28.
4
and hijack immunoglobulin light-chain enhancers in cyclin D1 mantle cell lymphoma.并劫持免疫球蛋白轻链增强子在套细胞淋巴瘤中的 cyclin D1 中。
Blood. 2019 Feb 28;133(9):940-951. doi: 10.1182/blood-2018-07-862151. Epub 2018 Dec 11.
5
Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.动态分子监测显示，SWI-SNF 突变介导套细胞淋巴瘤对伊布替尼联合维奈托克的耐药性。
Nat Med. 2019 Jan;25(1):119-129. doi: 10.1038/s41591-018-0243-z. Epub 2018 Nov 19.
6
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.肿瘤细胞程序性死亡配体 1 表达促进 T 细胞排除和对检查点阻断的抵抗
Cell. 2018 Nov 1;175(4):984-997.e24. doi: 10.1016/j.cell.2018.09.006.
7
Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.停止伊布替尼治疗的套细胞淋巴瘤（MCL）患者的长期结果和突变分析。
Br J Haematol. 2018 Nov;183(4):578-587. doi: 10.1111/bjh.15567. Epub 2018 Sep 2.
8
A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome.一个能够区分常规型和白血病性非结节性套细胞淋巴瘤的基因特征有助于预测预后。
Blood. 2018 Jul 26;132(4):413-422. doi: 10.1182/blood-2018-03-838136. Epub 2018 May 16.
9
Genomic landscape and prognostic analysis of mantle cell lymphoma.套细胞淋巴瘤的基因组景观和预后分析。
Cancer Gene Ther. 2018 Jun;25(5-6):129-140. doi: 10.1038/s41417-018-0022-5. Epub 2018 May 14.
10
Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.Voruciclib，一种临床阶段的口服 CDK9 抑制剂，可抑制 MCL-1 并使高危弥漫性大 B 细胞淋巴瘤对 BCL2 抑制敏感。
Sci Rep. 2017 Dec 21;7(1):18007. doi: 10.1038/s41598-017-18368-w.
Zotero 插件